Evaluation of Inflammatory Markers as Prognostic Factors in the Treatment of Hepatocellular Carcinoma (HCC) with Degradable Starch Microspheres by Transarterial Chemoembolization (DSM-TACE)

Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 647 - 647

Published: Feb. 14, 2025

Objective: To evaluate the prognostic value of pre-therapeutic inflammatory markers before transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in treatment hepatocellular carcinoma (HCC). Methods: A total 155 patients (81% male, median age: 68 years) who underwent first-time DSM-TACE between 07/13 and 06/22 were included study. Inflammatory indices dichotomized using values. Cox proportional hazard model for univariate (UVA) multivariate (MVA) analyses (hazard ratio; 95% CI, p-value) Kaplan-Meier (overall survival (OS) months; CI; log-rank test) performed. Results: The OS study cohort was 15.9 (12.9-20) months a according to BCLC stages (12%), B (41%), C (47%) not reached, 19.3 (15.3-27), 7.2 (4.5-9.0) months, respectively (p < 0.0001). In UVA, several on statistically significant systemic response index (SIRI; ≤median (2.04) HR: 0.41 (0.19-0.89); p = 0.024) lymphocyte monocyte ratio (LMR; >median (1.82) 0.44 (0.2-0.9); 0.025) remaining MVA together stage 0.0001), ALBI grade 0.016), hepatic tumor burden (≤25% vs. >25%; 0.006), largest HCC lesion (≤5.5 cm >5.5 cm; 0.008). subgroup analysis, elevated LMR reduced SIRI exhibited significantly prolonged overall both 0.0001) Child-Pugh 0.021) subgroups. Conclusion: findings suggest that may serve as valuable tools identifying could potentially benefit better from treatment. Nevertheless, further research is recommended confirm these provide more comprehensive insights.

Language: Английский

Exosome-based immunotherapy in hepatocellular carcinoma

Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 24, 2025

Language: Английский